Introduction. Incidence of meningioma increases with age. Surgery has been the
mainstay treatment. Elderly patients, however, are at risk of severe
morbidity. Therefore, we conducted this study to analyze long-term outcomes of
linac-based fractionated stereotactic radiotherapy (FSRT) for older adults
(aged ≥65 years) with meningioma and determine prognostic factors. Materials
and Methods. Between October 1998 and March 2009, 100 patients (≥65, median
age, 71 years) were treated with FSRT for meningioma. Two patients were lost
to follow-up. Eight patients each had grade I and grade II meningiomas, and
five patients had grade III meningiomas. The histology was unknown in 77 cases
(grade 0). Results. The median follow-up was 37 months, and 3-year, 5-year,
and 10-year progression-free survival (PFS) rates were 93.7%, 91.1%, and 82%.
Patients with grade 0/I meningioma showed 3- and 5-year PFS rates of 98.4% and
95.6%. Patients with grade II or III meningiomas showed 3-year PFS rates of
36%. 93.8% of patients showed local tumor control. Multivariate analysis did
not indicate any significant prognostic factors. Conclusion. FSRT may play an
important role as a noninvasive and safe method in the clinical management of
older patients with meningioma